A prospective, randomized, blinded, placebo-controlled, phase 2b trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine versus unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrence
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
Research Start Date
Status
Active
The purpose of this study is to (1) produce and test a vaccine that is made from a patient’s tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine (what side effects it has); and (3) to look at the immune system’s response to this vaccine.